Product Catalogwells Pharmacy Network

2020

PRODUCT CATALOGWELLS PHARMACY NETWORK

800-622-4510 [email protected] wellsrx.com A COMPOUNDING PHARMACY DEDICATED CONTENT TO QUALITY, SERVICE AND QUESTIONS 1 SAFETY. 503B LICENSING 2

Wells Pharmacy Network is a privately held nationwide compounding pharmacy specializing in wellness, anti- aging, weight management, sexual wellness, aesthetic PRODUCTS dermatology and thyroid and adrenal health. LIST OF PRODUCTS 3 Our mission is to elevate compounding industry standards through a unique combination of superior science and service. This includes operating a 21,000 503A pharmacy that meet the patients speciﬁ c compounding needs and as well as a 4,000 SF FDA Registered 503B Outsourcing Facility PELLETS that dispenses bulk medication for physician o ce use. ABOUT PELLETS 4 Wells Pharmacy Network uses the most advanced instrumentation, including in-house sterility and endotoxin STERILE 6 testing, which allow us to control the quality and timely IMPLANTABLE delivery of our preparations, such as sterile implantable HORMONE PELLETS bioidentical hormone pellets and other custom medications. Patient safety is our priority and our commitment to the quality of the preparations we compound is the most important thing we do each and every day.

Learn more at: WELLSRX.COM CONTENT

PEPTIDES AOD 9604 7 BPC-157 8 SEXUAL PRODUCTS CJC-1295/IPAMORELIN 9 WELLNESS DIHEXA 10 DSIP 11 PT-141 NASAL SPRAY 23 (EROS LOVE SPRAY) GHK-CU 12 SEXUAL WELLNESS 24 IBUTAMOREN 13 PROGRAM FOR IPAMORELIN 14 WOMEN KISSPEPTIN-10 15 SEXUAL WELLNESS 25 PROGRAM FOR MELATONAN II 16 MEN PEG-MGF 17 PT-141 18 (BREMELANOTIDE) KITS SEMAX 19 QUAD IMMUNE 26 SERMORELIN 20 THYMOSIN ALPHA 1 21 THYMOSIN BETA-4 22

WELLSRX.COM HAVE QUESTIONS? WE HAVE ANSWERS

800-622-4510 [email protected] wellsrx.com

MANAGEMENT CUSTOMER CARE TEAM AND OPERATIONS TEAM SUSAN NELSON, CPHT CUSTOMER SERVICE MANAGER KRIS FISHMAN [email protected] PRESIDENT PORTAL SUPPORT [email protected] CHRISTOPHER ULBRICHT VICE PRESIDENT OF OPERATIONS

MELISSA STEFKO MARKETING VICE PRESIDENT OF QUALITY ASSURANCE AND SALES TEAM

JUSTIN KIRKLAND EDUARDO PANTOJA VICE PRESIDENT OF PRODUCT DEVELOPMENT MARKETING DIRECTOR

HOWARD BROWN, R.PH JERRY GERMAIN PHARMACIST ASSISTANT VICE PRESIDENT OF SALES

TRACY JERNIGAN, PHARMD HEATHER VERMETTE PHARMACIST ASSISTANT VICE PRESIDENT OF SALES

JOHN MUNGER ROBBY HAMMERS VICE PRESIDENT OF ANALYTICS & PRICING ASSISTANT VICE PRESIDENT OF SALES

ANGIE ANDREWS TANNER SUER DIRECTOR OF OPERATIONS VISE PRESIDENT OF SALES

PX3 PORTAL SUPPORT [email protected] 2

WELLS PHARMACY 800-622-4510 [email protected] wellsrx.com LICENSING

MD DE

AK HI

503A & 503B LICENSE STATUS

503A & 503B STATES LICENSED

503A STATES LICENSED & PENDING 503B

503B STATES LICENSED / NO 503A

NOT LICENSED 3 Sterile Pellets Sterile pellets are used to treat hormone deﬁ ciencies and imbalances. They are a small and cylindrical dosage form, about the size of a grain of rice, containing comprehensed bio-identical hormones.

Peptides May improve hormonal balalnce and enhance energy, sleep quality, memory, sex drive and more by stimulation and release of hormones by the pituitary.

BHRT (Bio-Identical Hormone Replacement Therapy) Hormones that are the same molecular structure and function as those produced in the human body. Our BHRT formulations range in a variety of options such as oral, topical, sterile, implantable or sublingual.

Sexual Health Custom compounded solutions to improve sexual function. Used in conjunction with erectile dysfunction, vaginal dryness, low libido, and other conditions

Weight Management There are numerous factors that can a ect weight loss, including hormonal issues. Wells o ers a wide range of weight management solutions.

Thyroid & Adrenal The thyroid produces hormones that a ect metabolism which in turn impact energy, appetite, body temperature, heart rate, growth and more.

Aesthetic Dermatology A variety of pharmaceutical grade topicals to address common aesthetic issues and WHY USE PELLETS? help your patients achieve a look they love.

800-622-4510 877-401-5653 wellsrx.com [email protected]

Corporate O ce Ocala Pharmacy Dyersburg Pharmacy 503B Medication Questions or Concerns 3420 Fairlane Farms Road, Ste. 300 1210 SW 33rd Avenue 450 US Highway 51 BYP N Quality Hotline: 800-794-2360 Wellington, FL 33414 Ocala, FL 34474 Dyersburg, TN 38024 Email: [email protected] 3 4 ABOUT PELLETS ARE BIOIDENTICAL HORMONE REPLACEMENT PELLETS RIGHT FOR YOU?

WHAT ARE PELLETS? Sterile pellets are a small, cylindrical form of compounded medication prepared using bioidentical hormones. They are used to treat hormone deﬁ ciencies and imbalances in both men and women. The pellet is only about the size of a grain of rice and is implanted below the skin in the gluteal or abdominal area during a simple o ce procedure. The area is numbed using a local anesthetic and a tiny incision is made through which the pellet is inserted using a trocar. Once it is in place, a sterile strip is used to close the incision and covered with an adhesive bandage. Over the course of three to four months, the pellet slowly dissolves as the body draws small, physiologic dosages of the hormone to maintain a more consistent delivery. Once it is dissolved, “This statement has not been evaluated by the Food the procedure is repeated and a new pellet is inserted. and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

WHAT ARE PELLETS USED FOR?

Pellets have been used as a safe, e ective way to provide the body with hormones necessary for treatment of a wide variety of conditions. The doctor may prescribe sterile pellets for both men and women experiencing menopause or andropause, and with conditions such as:

• Testosterone deficiencies • Menstrual headaches • Low libido • Erectile dysfunction • Vaginal dryness • Depression • Urinary problems • Incontinence • Fatigue • Weight gain • Migraines

WHY USE PELLETS? One of the beneﬁ ts of pellets is that pellets can be used to deliver hormones to the body that are both structurally and biologically identical to the body’s own hormones. Bioidentical hormones such as estradiol (E2) and testosterone are the most commonly used ingredients. They are slowly released over a period of three to four months, allowing for more consistent delivery. Because the pellet is placed beneath the skin, once it is inserted, the body naturally does the rest. Patients do not have to remember to take a pill, apply a cream, or give an injection. Patients also do not have to worry about getting the pellet removed because it is safely dissolved by the body over time. Once it is dissolved, the next pellet can be inserted by the physician.

800-622-4510 [email protected] wellsrx.com

* THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL. ONLY YOUR PHYSICIAN CAN DETERMINE WHETHER A PARTICULAR FORMULATION IS RIGHT FOR YOU. 27 5 ABOUT PELLETS ARE BIOIDENTICAL HORMONE REPLACEMENT “This statement has not PELLETS RIGHT FOR YOU? been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

WHAT TO ASK YOUR DOCTOR ABOUT OUR PELLETS?

ARE PELLETS SAFE? Your doctor should look for pellets made in an FDA Registered 503B Outsourcing Facility to ensure the highest level of quality control. Also, ﬁ nd out if the pharmacy is using only active ingredients made from USP grade materials and if the chemicals used purchased from FDA registered facilities.

HOW ARE PELLETS MADE? Sterile implantable pellets are a safe, For a more natural product, like the type that Wells Pharmacy specializes in, look for sterile effective way to get implantable pellets that are created fusing together hormone powder and stearic acid without the exact dosage of the use of chemical binders. These compressed pellets are about the size of a grain of rice hormones your body and should be resistant to breakage and have a consistent color and texture for higher quality needs for improved results that you and your doctor can be confi dent in. health and wellbeing. HOW CAN I BE SURE THAT PELLETS ARE RIGHT FOR ME? Verify that your physician has access to a variety of strengths and compositions and that To fi nd out more about your doctor can prescribe the pellets for your specifi c needs. This further ensures that you how you could benefi t are getting the proper dosage of each hormone for your condition. Confi rm that all orders from this specially compounded medication, are verifi ed once they are received for accuracy and completeness and go through extensive talk to your doctor safety and sterility testing before leaving the facility. This will allow you to rest assured that today or visit the Wells the pellet you are receiving is compliant not only with high quality testing standards, but also Pharmacy Network prepared to meet your needs. website:

wellsrx.com/sterile-pellets WHAT IF I NEED THEM IMMEDIATELY? It can be hard to predict when you may need a prescription. To avoid delays in treatment, ensure your physician works with a company that o ers overnight shipping for faster delivery of your medications.

800-622-4510 [email protected] wellsrx.com

* THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL. ONLY YOUR PHYSICIAN CAN DETERMINE WHETHER A PARTICULAR FORMULATION IS RIGHT FOR YOU. 5 FDA REGISTERED 503B OUTSOURCING FACILITY 6 STERILE IMPLANTABLE HORMONE PELLETS

OUR STERILE IMPLANTABLE HORMONE PELLETS Wells Pharmacy Network now has an FDA WHAT TO ASK YOUR DOCTOR Registered 503B Outsourcing Facility in ABOUT OUR PELLETS? Tennessee for the production of sterile implantable hormone pellets. The new “gold standard” for pellet production are in compliance with the FDA’s standards for CGMP (current good manufacturing practices), the same as large commercial drug manufacturers.

QUALITY & SAFETY • Highest quality and potency • Consistent color and texture Call your Account • Resistant to breakage Sales Team or email • Active ingredients made using USP grade materials derived from yam [email protected] • Chemicals purchased from FDA registered facilities to place your • PVP free order today. • Irradiation sterilization via E-Beam sterilizes the pellet and the blister pack enclosure • Pellet dedicated pharmacists available to answer your questions

EASY ORDERING

Bulk orders shipped to your office No minimum orders Faster turnaround time

800-622-4510 [email protected] wellsrx.com

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

AODADVANCED OBESITY9604 DRUG (MODIFIED PEPTIDE FRAGMENT OF HIGH) DESCRIPTION AOD 9604 is a modifi ed form of amino acids 176-191 of the GH polypeptide. MOLECULAR FORMULA C78H123N23O23S2 Investigators at Monash University discovered that the MOLECULAR WEIGHT 18115.1 fat-reducing e ects of GH appear to be controlled by a small region near one end of the GH molecule. This region, SEQUENCE Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser- which consists of amino acids 176-191, is less than 10% of Val-Glu-Gly-Ser-Cys-Gly-Phe the total size of the GH Molecule and appears to have no e ects on growth or insulin resistance. This hypothesis was proven in animals to a tremendous degree with specimen losing a signifi cant amount of fat PROTOCOL mass. However, in phase three clinical trials the peptide didn’t mean its confi dence interval. Instead, it is now being CONTENT & POTENCY studied for its e ect on bone and cartilage. INJECTABLE: 1200mcg/ml subcutaneous AOD 9604 possesses many other regenerative properties injectable provided in a 5ml vial. associated with growth hormone. Currently trials are underway to show the application of AOD 9604 in SUGGESTED DOSAGE osteoarthritis, Hypercholesterolemia, bone and cartilage INJECTABLE: Inject 0.25ml subcutaneously repair. AOD 9604 has an excellent safety profi le, recently once daily for 20 days. obtaining Human GRAS status in the USA.

Safety and Tolerability of the Hexadecapeptide AOD 9604 CLINICAL in Humans Heike Stier, Evert Vos, David Kenley RESEARCH Backgroud: The human growth hormone (hGH) has fat loss properties making it a potential candidate to treat obesity. AOD 9604 is a peptide fragment of theC-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD 9604 obtained in clinical trials are summarized. Methods: Six randomized, double-blind, placebo-controlled trials were performed with AOD 9604. Special focus was given to undesired effects associated with hGH treatment: increases in IGF-1 levels, insulin resistance, and impaired glucose tolerance. Blood samples were analyzed for presence of antiAOD 9604 antibodies to exclude immunogenicity. Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604. Conclusion: AOD 9604 displayed a very good safety and tolerability profile indistinguishable from placebo. AOD 9604 did not result in any of the adverse effects associated with full-length hGH treatment.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 7 8 BPC-157 PHYSICIAN EDUCATION

WHAT IS BPC-157? BPC-157 is a pentadecapeptide made up of BENEFITS 15 amino acids. It is a partial sequence of the body protection compound (BPC) derived Patient benefi ts over time may from human gastric juice. Experiments have include: shown that it heightens the healing of many • Accelerated wound healing di erent types of tissues, including: tendon, muscle, nervous system, and is superior at • Decreases inflamation healing damaged ligaments. • Increased fibroblast Patients who su er from discomfort due to sprains, tears, and tissue damage may benefi t • Nitric oxide improvement from treatment with this peptide as it can increase blood fl ow back to the injured sites. • Improves digestive function BPC-157 may protect organs, prevent stomach • Enhanced vascular expression of VEGFR2 ulcers, and heal skin burns.

TYPICAL PRESCRIBING PROTOCOL: • Prescribing is often based on body weight using 2mcg/kg to as much as 10mcg/kg twice daily. • Commonly used doses range from 200mcg to 400mcg twice daily (400mcg to 800mcg daily). • If used twice daily, intramuscular injection as close to the injury as possible or via subcutaneously for systemic purposes. • Use for 2-4 weeks before discontinuing; cease therapy for 2 weeks, then restart therapy if needed.

800-622-4510 [email protected] wellsrx.com

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

REFERENCE: CHANG, CH, ET AL. “THE PROMOTING EFFECT OF PENTADECAPEPTIDE BPC 157 ON TENDON HEALING INVOLVES TENDON OUTGROWTH, CELL SURVIVAL, AND CELL MIGRATION.” HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/21030672, 11 MAR. 2011, WWW.NCBI.NLM.NIH.GOV/ PUBMED/21030672.

“This statement has not been evaluated by the Food and Drug Administration. This WHAT IS CJC-1295? product is not intended to diagnose, treat, CJC-1295 is a tetrasubstituted 29-amino acid Growth Hormone cure, or prevent any disease.” Releasing Hormone (GHRH) analog. It stimulates a release of HGH and IGF-1 without raising prolactin levels, leading to fat loss and increased protein synthesis thereby promoting growth of muscle. Our CJC-1295 is compounded without DAC (Drug A nity Complex) which provides a more e ective GH spike resembling a normal physiologic release of GH. BENEFITS Patient beneﬁ ts over time may WHAT IS IPAMORELIN? include: HOW IS IT USED WITH CJC-1295? • Promotes slow wave sleep Ipamorelin Acetate is a Growth Hormone Releasing Peptide (GHRP) that assists increasing the amount of growth hormone • Improves memory retention released. Ipamorelin is a pentapeptide composed of ﬁ ve amino acids and has a biological half-life of 2 hours after administration. • Stimulates muscle growth It is widely known for being able to suppress somatostatin or Growth Hormone Inhibiting Hormone (GHIH). Using CJC-1295 • Aids in fat loss & lean muscle in conjunction with Ipamorelin may be more e ective in the production of growth hormone secretion, and in helping speed recovery time after an injury.

TYPICAL PRESCRIBING PROTOCOL: • Beneﬁ ts can be seeing using as little as 100mcg of each CJC-1295/Ipamorelin. • Injections can be done before bed or TID. • Recommended to take at least 30 minutes away from food. • Patients with a higher BMI or high estrogen levels may require larger doses.

RECOMMENDED TREATMENT PLANS BASED ON EACH VIAL LASTING 30 DAYS:

30 doses 0.07cc (7 units) subcutaneous 20 doses 0.10cc (10 units) subcutaneous 40 doses 0.05 cc (5 units) subcutaneous A provides 133mcg/133mcg per injection B provides 200mcg/200mcg per injection C provides 100mcg/100mcg per injection (AM + PM)

800-622-4510 [email protected] wellsrx.com

MOLECULAR FORMULA C27H44N4O5 MOLECULAR WEIGHT 504.672 g/mol CHEMICAL NAME N-hexanoic-Tyr-Ile-(6) DESCRIPTION DIHEXA is a peptide variant derived from angiotensin IV. aminohexanoic amide Clinical studies suggest that DIHEXA improves cognitive function as shown in animal models of disease such as Alzheimer’s. Angiotensin IV is a derivative of the PROTOCOL vasoconstrictor angiotensin II which has been shown in animal studies to enhance acquisition, consolidation CONTENT & POTENCY BENEFITS and recall of learning and memory when administered CREAM: 20 mg/mL transdermal cream provided in a 30 mL applicator. centrally or peripherally. In an assay of neurotrophic CAPSULE: 10 mg and 20 mg oral capsule. activity, DIHEXA was found to be seven orders of magnitude more potent than brain-derived neurotrophic SUGGESTED DOSAGE • Promotes slow wave sleep CREAM: Apply 0.5-1 mL (2-4 clicks) to inner factor and is thought may be able to help in the repair forearm daily, rub in until absorbed. of the brain and nerves in neurological disease. • Improves memory retention CAPSULE: Take 1 capsule by mouth daily. • Stimulates muscle growth Benoist CC, Kawas LH, Zhu M, et. al. • Aids in fat loss & lean muscle The Procognitive and Synaptogenic e ects of Angiotensin IV- CLINICAL Derived Peptides are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. J. Pharmacol Exp Ther. 2014 RESEARCH Nov;351(2):390-402. doi: 10.1124/jpet. 114.218735. Epub 2014 Sep 3 A subset of angiotensin IV (AngIV)–related molecules are known to possess procognitive/antidementia properties and have been considered as templates for potential therapeutics. However, this potential has not been realized because of two factors: 1) a lack of blood-brain barrier–penetrant analogs, and 2) the absence of a validated mechanism of action. The pharmacokinetic barrier has recently been overcome with the synthesis of the orally active, blood-brain barrier–permeable analog N-hexanoic-tyrosine- isoleucine-(6) aminohexanoic amide (dihexa). Therefore, the goal of this study was to elucidate the mechanism that underlies dihexa’s procognitive activity. Here, we demonstrate that dihexa binds with high affinity to hepatocyte growth factor (HGF) and both dihexa and its parent compound Norleucine 1-AngIV (Nle1-AngIV) induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering. Further, dihexa and Nle1-AngIV induce hippocampal RECOMMENDED TREATMENT PLANS BASED ON EACH VIAL LASTING 30 DAYS: spinogenesis and synaptogenesis similar to HGF itself. These actions were inhibited by an HGF antagonist and a short hairpin RNA directed at c-Met. Most importantly, the procognitive/antidementia capacity of orally delivered dihexa was blocked by an HGF antagonist delivered intracerebroventricularly as measured using the Morris water maze task of spatial learning.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 81 11

DSIPDELTA SLEEP INDUCING PEPTIDE

MOLECULAR FORMULA C35H48N10O15 MOLECULAR WEIGHT 848.81 SEQUENCE Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu DESCRIPTION DSIP is a naturally occuring somnogenic nonapeptide with possible physiological functions impacting neuromodulation. DSIP is typically found in the PROTOCOL brain and easily passes the blood-brain barrier. Studies indicate that DSIP and its analogues are best classified as peptide neuromodulators. DSIP CONTENT & POTENCY 1 mg/mL subcutaneous injection provided has been shown to exhibit a pronounced stress in a 3 mL vial. protective action and demonstrated a decrease in stress-induced metabolic disorders in both SUGGESTED DOSAGE human and animal models. It is believed that Inject 0.1 mL subcutaneously once daily DSIP works by modulating activity of GABAergic, at bedtime. glutamatergic, and other neuronal systems.

Miller LH, Turnbull BA, Kastin AJ, et. al. Sleep-Wave Activity CLINICAL of a Delta Sleep-Inducing Peptide Analog Correlates with its RESEARCH Penetrance of the Blood-Brain Barrier. Sleep. 1986;9(1):80-4

In several species DSIP at low doses has been shown to promote sleep. Although its physiological role remains to be clariﬁ ed, DSIP illustrates several concepts applicable to other brain peptides. These include the bell-shaped dose-response curve, central e ects after peripheral administration, a delayed and prolonged time course, and some penetration of the blood-brain barrier in essentially intact form. Concepts applicable to one neuropeptide, therefore, appear to be applicable to others. In this article Abba Kastin and colleagues review the known e ects of DSIP and argue that more work needs to be carried out before it can be labelled functionally.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 11 12

GHK-CuCOLLAGEN & AESTHETIC PEPTIDE DESCRIPTION GHK-Cu is a naturally occurring copper complex that was fi rst identifi ed in human plasma, but has since been found MOLECULAR FORMULA C28H52CuN12O8 in multiple locations such as saliva and urine. Copper MOLECULAR WEIGHT 748.346 g/mol peptides are small, naturally occurring protein fragments that have high a nity for copper ions, which evidence SEQUENCE Gly-His-Lys(cu2+) suggests are critical to normal body function. Clinical studies indicate that GHK-Cu has a variety of roles in the human body including, but not limited to, promoting activation of wound healing, attracting immune cells, PROTOCOL antioxidant and anti-infl ammatory e ects, stimulating collagen and glycosaminoglycan synthesis in skin CONTENT & POTENCY fi broblasts, and promoting blood vessel growth. There has INJECTABLE: 10 mg/mL subcutaneous injection been some clinical evidence that has shown that GHK-Cu provided in a 5 mL vial. TRANSDERMAL (SCALP): 5 mg/mL (0.5%) topical acts as a feedback signal generated after tissue injury foam provided in a 50 mL foaming applicator. and it may act as a potent protector of tissue and anti- TRANSDERMAL (FACIAL): 5 mg/mL (0.5%) facial infl ammatory agent possibly by reducing the oxidative cream provided in a 15 gm pump. damage that occurs post-tissue injury. Further, GHK-Cu has been found to be involved in signaling tissue remodeling by SUGGESTED DOSAGE removing damaged/scarred tissue and generating healthy INJECTABLE: Inject 0.2 mL subcutaneously once tissue. It has been shown in studies that GHK concentration daily. decreases with age because the concentration of GHK-Cu TRANSDERMAL (SCALP): Apply 2-3 pumps to scalp once daily at night. in the body decreases with age which may result is an TRANSDERMAL (FACIAL): Apply 1-2 pumps to increase in infl ammation, cancerous activity, and tissue face and rub in at night. destruction.

Pickart L, Vasquez-Soltero JM, Margolina A. CLINICAL GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015;2015:648108. RESEARCH doi: 10.1155/2015/648108. Epub 2015 Jul 7. GHK (glycyl-L-histidyl-L-lysine) is present in human plasma, saliva, and urine but declines with age. It is proposed that GHK functions as a complex with copper 2+ which accelerates wound healing and skin repair. GHK stimulates both synthesis and breakdown of collagen and glycosaminoglycans and modulates the activity of both metalloproteinases and their inhibitors. It stimulates collagen, dermatan sulfate, chondroitin sulfate, and the small proteoglycan, decorin. It also restores replicative vitality to fibroblasts after radiation therapy. The molecule attracts immune and endothelial cells to the site of an injury. It accelerates wound-healing of the skin, hair follicles, gastrointestinal tract, boney tissue, and foot pads of dogs. It also induces systemic wound healing in rats, mice, and pigs. In cosmetic products, it has been found to tighten loose skin and improve elasticity, skin density, and firmness, reduce fine lines and wrinkles, reduce photodamage, and hyperpigmentation, and increase keratinocyte proliferation. GHK has been proposed as a therapeutic agent for skin inflammation, chronic obstructive pulmonary disease, and metastatic colon cancer. It is capable of up- and downregulating at least 4,000 human genes, essentially resetting DNA to a healthier state. The present review revisits GHK’s role in skin regeneration in the light of recent discoveries.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 7 13 IBUTAMOREN MESYLATE PHYSICIAN EDUCATION

WHAT IS IBUTAMOREN MESYLATE Ibutamoren is classiﬁ ed as a non-peptide growth BENEFITS hormone secretagogue and mimics the growth hormone stimulating action of ghrelin. Ibutamoren Patient beneﬁ ts over time may is considered to be potent, long-acting, and include: available through oral administration. Clinically, it has been demonstrated to increase endogenous release of growth hormone (GH) as well as insulin- • Increase muscle mass like growth factor 1 (IGF-1) without the adverse • Decrease fat mass increase of prolactin or cortisol often seen with GHRPs. Additionally, increases in lean body mass • Faster healing can be achieved while lowering LDL cholesterol. Studies have shown Ibutamoren stimulates brain • Firmer healthier skin regions involved with metabolic action, such as the hypothalamus and the pituitary. Ibutamoren • Healthier hair may be e ective in increasing both muscle • Improved quality sleep mass and bone mineral density, making it a promising therapy for the treatment of frailty and • Combats aging osteoporosis in the elderly.

TYPICAL PRESCRIBING PROTOCOLS:

• Ibutamoren is available as a 10 mg or 25 mg oral tablet. As opposed to some of our other sublingual tablets, it is intended to be swallowed. The tablet can be split in order to deliver a lower dose for a speciﬁ c patient and is commonly prescribed at bedtime once daily. • The Ibutamoren clinical studies were conducted over short durations of up to 8 weeks. Therefore, taking an initial IGF-1 baseline and then taking periodic blood tests early on during therapy is suggested. • Reach out to your Account Representative today to get more information on Ibutamoren or to place an order. If you don’t know who to contact, call 800.622.4510, or email [email protected]

800-622-4510 [email protected] wellsrx.com

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

WHAT IS IPAMORELIN ACETATE? BENEFITS Ipamorelin Acetate is a Growth Hormone Releasing Peptide (GHRP) that stimulates the pituitary gland within the body to release natural growth hormone (GH). Ipamorelin Acetate is a pentapeptide composed of fi ve Patient benefi ts over time may amino acids and has a biological half-life of 2 hours after administration. include: It is widely known for being able to suppress somatostatin or growth inhibiting hormone. • Aid in the body’s ability to burn fat As we age, our hormone levels fl uctuate interfering with patient’s overall quality of life. Imbalances can result in loss of energy, increased • Helps improve lean muscle mass irritability, sleeplessness, memory problems, and low sex drive. Utilizing peptide therapy separately or in conjunction with hormone replacement • Supports immune system may restore optimal hormone levels in your patients. Studies suggest • Improved sex drive that Ipamorelin Acetate did not a ect FSH, LH, Prolactin, or TSH levels. Furthermore, Ipamorelin did not seem to have an impact on cortisol and • Strengthened cardiovascular system ACTH levels during GHRH stimulation. • Improved quality of sleep WHY WOULD I WANT TO USE IPAMORELIN? • Improved energy and endurance With age, our hormone levels fl uctuate and often decline interfering with a patient’s overall quality of life. Imbalances can result in loss of energy, • Supports bone density increased irritability, sleeplessness, memory problems, and low sex drive. • Improved skin fi rmness and moisture Utilizing peptide therapy separately or in conjunction with hormone retention replacement may restore optimal hormone levels in your patients. Studies suggest that Ipamorelin Acetate does not clinically a ect FSH, • Improved cognition and memory LH, Prolactin, or TSH levels. Furthermore, Ipamorelin did not seem to have a clinically adverse impact on cortisol or ACTH levels.

WHAT STRENGTHS & FORMS ARE AVAILABLE? WHAT YOU NEED TO KNOW? Reach out to your Account Representative today to get more Discuss with your physician to see if Ipamorelin would be right for you. information on Ipamorelin or to place an order. If you don’t Ipamorelin injectable therapy can only be used under a physicians care. know who to contact, call 800.622.4510, or email With Ipamorelin therapy, you may notice improved recovery after workouts [email protected] and better quality of sleep. Always inform your physician about changes in medications and supplements. Common side e ects, as with any “This statement has not been evaluated by the Food injectable medication, may include injection site reaction such as pain at and Drug Administration. This product is not intended to the injection site. diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com

REFERENCE: HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/9849822 * THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL. 15 KISSPEPTIN-10 DESCRIPTION Kisspeptin-10 is an endogenous neuropeptide product of the KISS1

MOLECULAR FORMULA C63H83N17O14 gene. It acts as a modulator of the Hypothalamus-Pituitary-Gonad Axis (HPG). This peptide stimulates the secretion of gonadotrophin-releasing MOLECULAR WEIGHT 1302.4 g/mol hormone (GnRH) at an upstream position. Animal and human studies CHEMICAL NAME Try-Asn-Trp-Asn-Ser-Phe- show an increase in luteinizing hormone and follicle-stimulating hormone post Kisspeptin-10 administration. Kisspeptin performs this Gly-Leu-Arg-Phe-NH2 function by directly sending signals to GnRH neurons.

Kisspeptin may be a beneﬁ cial addition to a Testosterone Replacement Therapy (TRT) program. With TRT therapy, higher levels of testosterone act on the pituitary through the Hypothalamic-Pituitary-Gonadal PROTOCOL Axis negative feedback loop to inhibit the release of GnRH and correspondingly reduce the pulse frequency of Luteinizing Hormone. CONTENT & POTENCY Without the presence of LH, the testicles will cease producing Each 2ml sterile vial of Kisspeptin-10 contains testosterone, deﬁ ned as hypogonadism, which can lead to a reduction 2mg of Kisspeptin-10. in testicle size. Kisspeptin is used to counteract the reduced LH pulse frequency by increasing the frequency of the GnRH pulse. Additionally, SUGGESTED DOSAGE stimulation to the Leydig cells can occur resulting in an increase in Inject 0.1ml subcutaneously twice weekly. testosterone production.

CLINICAL FRONT ENDOCRINOL (LAUSANNE). RESEARCH 2015; 6:45 DOI:10.3389/FENDO.2015.00045

The HPG axis is controlled by a negative feedback loop. In the healthy brain, the hypothalamus releases gonadotropin-releasing hormone (GnRH) into the median eminence, and then GnRH is transported via the hypophyseal portal system to the anterior pituitary where it acts on its receptor (GnRHR). Signaling from GnRHR leads to the production and secretion of the gonadotropins, including luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Once the gonadotropins are secreted into the bloodstream, LH acts on its receptor in the gonads, which in turn stimulates the release of the sex steroids, androgens, and estrogens. These sex steroids complete a negative feedback loop by inhibiting the release of GnRH.

Kisspeptin-10 can possibly be used as an alternative to HCG in male patients with testicular atrophy with dosing optimized by measuring FSH and LH via blood work. Recommended dosing for use in conjunction with Testosterone Replacement Therapy to maintain fertility and deter against testicular atrophy is 2-3 times per week at 0.1ml−0.2ml per injection from a 1mg/ml sterile vial. Dosing can be adjusted linearly if using as a substitute for HCG. LabCorp reference values for adult males for FSH are at 1.5−12.4 (mIU/mL) and 1.7−8.6 (mIU/ mL) for LH.

Dosing should be monitored by regular blood work measuring Luteinizing Hormone and Follicle Stimulating Hormone.

Prolonged use has not been evaluated. Administration of multiple doses daily has been associated with tachyphylaxis. “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 15 16 MELANOTAN II TANNING AND FAT LOSS DESCRIPTION 50 69 15 9 MOLECULAR FORMULA C H N O Melanotan I and Melanotan II are both analogs of MOLECULAR WEIGHT 1024.2 the peptide hormone alphamelanocyte stimulating hormone (a-MSH) that induces skin tanning. Like SEQUENCE Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys- its predecessor, Melanotan I, MT 2 plays a role in NH2(cyclic 2-7) stimulating melanogenesis and thus provides a protective mechanism against UV rays since under its actions melanocytes are able to increase PROTOCOL production and secretion of the hormone melanin. Scientists have also noticed that MT 2 had a positive CONTENT & POTENCY e ect on libido due to its aphrodisiac properties. INJECTABLE: 5ml at 2000mcg/ml : ready-to- Additionally, MT 2 exhibits a mild positive fat- inject subcutaneously mobilizing e ect. Melanotan I is an FDA approved SUGGESTED DOSAGE drug under the brand name Scenesse. Scenesse is INJECTABLE: 0.15ml daily for 1 - 2 weeks most commonly used to treat patients that have an then 0.25mL twice weekly for maintenance. intolerance to light.

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, CLINICAL Hadley ME. Source: College of Medicine, Pharmacology RESEARCH Department, University of Arizona, Tucson, USA.

Abstract: A pilot phase I study was conducted with a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9- Lys10 alpha-MSH4-10-NH2 (MT-II) and has superpotent melanotropic activity in vitro. A single-blind, alternating day (saline or MT-II), placebo-controlled trial was conducted in 3 normal male volunteers at the starting dose of 0.01 mg/kg of MT-II. Subcutaneous injections of MT-II or saline were given daily (Monday-Friday) for 2 consecutive weeks. Two subjects were escalated by 0.005 mg/kg increments to 0.03 mg/kg and one to 0.025 mg/kg. The 0.03 mg/kg dose produced Grade II somnolence and fatigue in one of two subjects (WHO standards). Mild nausea, not requiring antiemetic treatment, was reported at most MT- II dose levels. A stretching and yawning complex appeared to correlate with the onset of spontaneous, Penile erections which were intermittently experienced for 1-5 hours after MT-II dosing, depending on the MT-II dose. Two subjects had increased pigmentation in the face, upper body and buttock, as measured by quantitative reflectance and by visual perception 1 week after MT-II dosing ended. These results demonstrate that MT-II has tanning activity in humans given only 5 low doese every other day by subcutaneous injection. The recommended single MTII dose for future Phase I studies is 0.025 mg/kg/day.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 17 PEG-MGF MECHANO GROWTH FACTOR

MOLECULAR FORMULA C121H200N42O39 MOLECULAR WEIGHT 4867 SEQUENCE Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys- Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr- DESCRIPTION MGF is a split variant of IGF-1 and differs from the Phe-Glu-Glu-Arg-Lys systemically produced IGF-1. It is believed that IGF-I is spliced towards MGF thereby possibly initiating muscle hypertrophy and repair of local PROTOCOL damage. Studies show that MGF is expressed by mechanically overloaded muscle and may be CONTENT & POTENCY involved in tissue repair and adaptation. MGF is 2 mg/mL subcutaneous injection provided in a 5 mL vial. PEGylated, in order to increase the half-life.

SUGGESTED DOSAGE Inject 0.1 mL subcutaneously once daily 5 out of 7 days of the week.

Philippou A, Papageorgiou E, Bogdanis G. et. al. Expression CLINICAL of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in RESEARCH vitro. In Vivo 2009 Jul-Aug;23(4):567-75. Abstract: Di erent insulin-like growth factor-1 (IGF-1) isoforms, namely IGF-1Eb and IGF-1Ec (MGF),have been proposed to have various functions in muscle repair and growth. To gain insight into the potentially di erential actions of IGF-1 isoforms in the regulation of muscle regeneration, we assessed the time course of their expressions at both mRNA and protein levels after exercise-induced muscle damage in humans. In addition, we characterized mature IGF-1 and synthetic MGF E peptide signalling in C2C12 myoblast-like cells in vitro. Ten healthy male volunteers were subjected to exercise-induced muscle damage and biopsy samples were taken from the exercised muscles before and 6 h, 2,5 and 16 days post exercise. Muscle damage was documented by specifi c functional and biochemical responses post exercise. PCR-based analyses of muscle biopsy samples revealed a rapid and transient up-regulation of MGF mRNA expression which was followed by a prolonged increase of IGF-1Ea and IGF-1Eb mRNA expression (p<0.05). Patterns similar to those for mRNA expression were detected for MGF and IGF-1Ea expression at the protein level. The action of synthetic MGF E peptide di ered from that of mature IGF1 since its proliferative e ect on C2C12 myoblast-like cells was not blocked by an anti-IGF-1 receptor neutralizing antibody and it did not phosphorylate Akt. Therefore, we conclude that the di erential expression profi le of IGF-1 isoforms in vivo and the possible IGF-1R- independent MGF E peptide signaling in skeletal muscle-like cells in vitro support the notion that tissue-specifi c mRNA expression of MGF isoform produces mature IGF-1 and MGF E peptides which possibly act as distinct mitogens in skeletal muscle regeneration.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 17 18 PT-141 PHYSICIAN EDUCATION

WHAT IS PT-141? BENEFITS PT-141 was developed from the peptide Patient beneﬁ ts over time may Melanotan 2, which is a synthetically produced include: variant of a peptide hormone naturally produced in the body that stimulates melanogenesis that • Improves female sexual arousal disorder is known as alpha- Melanocyte stimulating hormone. PT-141 has been shown in studies to • Improve sexual function in men (such as provide libido-enhancing e ects by activating erectile dysfunction or impotence) the melanocortin receptors MC1R and MC4R, without tanning the skin. PT-141 is a potential remedy for the treatment SIDE EFFECTS of female sexual dysfunction and male erectile dysfunction. Studies have shown that PT-141 does Side e ects for males and females may not act on the vascular system, but may increase include: sexual desire through the nervous system. • Nausea • Flushing • Headache

TYPICAL PRESCRIBING PROTOCOL: MALE: • Males with no history of ED may begin with 1mg (0.1mL) via subcutaneous injection in the lower right quadrant of abdomen at least 45 minutes prior to sexual activity (titrating dose upward to e ect as needed or tolerated).

• Males with a history or diagnosis of ED with inadequate response to Sildenaﬁ l 100mg may begin with 4mg (0.4mL) via subcutaneous injection in the lower right quadrant of abdomen approximately 45 minutes prior to sexual activity (titrating dose upward to e ects as needed or tolerated).

FEMALE: • Females with FSAD or HSDD may begin with 750mcg - 1mg (0.075mL - 0.1mL) via subcutaneous injection (titrating dose upward to e ect as needed or tolerated) at least 45 minutes prior to sexual activity. Recommended to use no more than two times per week.

800-622-4510 [email protected] wellsrx.com

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

REFERENCE: SHADIACK, AM, ET AL. “MELANOCORTINS IN THE TREATMENT OF MALE AND FEMALE SEXUAL DYSFUNCTION.” PUBMED.GOV, 2007, WWW.NCBI.NLM.NIH.GOV/PUBMED/17584134.

SEMAXNEUROPEPTIDE

MOLECULAR FORMULA C37H51N9O10S MOLECULAR WEIGHT 813.92 g/mol SEQUENCE Met-Glu-His-Phe-Pro-Gly-Pro DESCRIPTION Heptapeptide SEMAX (MEHFPGP) is the analogue of ACTH (4-10) that has a demonstrated prolonged PROTOCOL neurotropic activity. This has historically been used in patients with pathologies related to CONTENT & POTENCY 1 mg/mL subcutaneous injection provided brain circulation dysfunction. It has also been in a 5 mL Vial. suggested in literature that due to its e ect on carboxypeptidase it may also increase physical SUGGESTED DOSAGE Inject 0.3-1 mL subcutaneously twice per performance and adaptation capacities in week, depending on patient response. exposure to high intensity exercise and at higher doses, >0.5 mg/kg, may exhibit analgesic Often prescribed for: Anti-Thrombosis, like e ects. ADHD/Learning, Gastric protection, Physical exertion improvement pain, Metal toxicities.

Manchenko DM, Glazova Nlu, Levitskaia NG, et. al. CLINICAL Nootropic and Analgesic Effects of Semax Following Different Routes of Administration. Ross Fiziol Zh Im I M Sechenova. 2010 RESEARCH Oct; 96(10):1014-23. The heptapeptide Semax (MEHFPGP) is an analog of the fragment ACTH(4–10) with long-lasting actions.The aim of the present work was to study the effects of Semax on learning ability and pain sensitivity in white rats given different doses via the intraperitoneal and intranasal routes. The nootropic effects of Semax were studied in a test based on the acquisition of a conditioned passive avoidance reaction to pain stimulation. Pain sensitivity was assessed in a hindpaw compression test. The results showed that i.p. Semax had nootropic and analgesic actions. Dose- response characteristics were different for these different effects. Intranasal Semax was more effective in improving learning in animals than i.p. Semax but had no effect on pain sensitivity. Our results provide evidence that different mechanisms and brain structures are involved in mediating the nootropic and analgesic effects of Semax.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 19 “This statement has not been 20 evaluated by the Food and Drug Administration. This product is SERMORELIN not intended to diagnose, treat, PHYSICIAN FAQs cure, or prevent any disease.”

HOW TO RECONSTITUTE WHAT IS INCLUDED WITH THE LYOPHILIZED VIALS SHIPMENT? In each shipment from Wells Pharmacy, the patient will be provided the We recommend the following for any size vial to calculate following for each kit ordered: a 30 day supply: • Vial of medication • 6mg Vial with 6mL reconstitution; • Vial of diluent (0.2mL=200mcg) & (0.3mL=300mcg) • MIxing syringe with an attached needle • 9mg Vial with 6mL reconstitution; • #2 alcohol pads for mixing purposes (0.2mL=300mcg) & (0.3mL=450mcg) *All supplies for injections are sold separately • 15mg Vial with 6mL reconstitution; (0.2mL=500mcg) & (0.3mL=750mcg)

*Make sure that your patient knows that a sterile multi-use WILL MY PATIENTS EXPERIENCE HUNGER? vial should be discarded after 28-30 days. It can be caused for some by the stimulation of ghrelin for a small percentage of patients using GHRP-6. CAN I DOSE BY WEIGHT OR BMI? THE IGF-1 LABS DID NOT CHANGE? If dosing based on BMI, this requires adjustments for male/ female patients due to the blunting e ect estrogren has on The feedback from the patient on how they are feeling is equally GH/IGF-1 production. Also, BMI should not be totally relied important as the lab testing. Remember, that you are treating a upon for dosing as BMI does not take into account lean muscle patient and not a number. In some patients the dosage may need to be titrated up or converted to a blend of all 3 (GHRH/GHRP-2/GHRP-6) mass. The patient’s overall health and ﬁ tness status should be to experience results. (It is important that the labs are measured at considered rather than dosing based on a number value from a the same time every time). patient’s weight and height alone.

BMI MEN WOMEN PATIENTS ON PREVIOUSLY ON HUMAN 18-24 200mcg 300mcg GROWTH HORMONE WILL THIS WORK? 25-29 400mcg 400-500mcg Yes, however in some rare cases Sermorelin therapy will not work if somatostatin has inhibited all GH production. High levels of GH can cause an increase in somatostatin via the feedback look and decrease GH production. Because GHRP inhabits somatostatin, the addition of GHRP to SIDE EFFECTS Sermorelin will assist in decreasing somatostatin; thereby, increasing the Most common is injection site reaction (pain; redness; number of somatotrophs and subsequently increase somatropin and GH swelling). Less than 1% dizziness, fl ushing, headache or production to a larger extent than using Sermorelin alone. hyperactivity. POSSIBLE OVERDOSE? WHAT IS THE MINIMUM AMOUNT OF No, due to the saturation e ect. This therapy has also been shown to TIME A PATIENT SHOULD TAKE help to rebuild and preserve pituitary function for many patients. BEFORE THEY SEE RESULTS? Most patients will begin to feel sleep changes in the fi rst IS THIS PRODUCT FDA APPROVED? week. For best results patients should commit to using for Sermorelin was FDA approved in 1997 to treat GH defi ciency, in 2002 90 days to feel the full benefi ts. Geref from Serono was discontinued in part due to the high cost. The chemicals purchased by Wells Pharmacy are from FDA approved WHAT IF MY PATIENT DID NOT facilities and vendors. SEE A CHANGE THEY HOPED FOR? HALF-LIFE? Just as with BHRT therapy changes in the body are measured in both the labs and in the feedback from your patients. It’s Sermorelin has a half-life of 11-12 minutes following subcutaneous important to discuss both as well as their expectations. administration *Per original package insert.

800-622-4510 [email protected] wellsrx.com 21 21 THYMOSIN ALPHA 1

MOLECULAR FORMULA C129H215N33O55 MOLECULAR WEIGHT 3108.3 g/mol DESCRIPTION SEQUENCE Ac-Ser-Asp-Ala-Ala--Val-Asp-Thr-Ser-Ser-Glu- Thymosin Alpha 1 (TA1) is a peptide originally Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu- isolated from thymic tissue and is a compound believed to be responsible for restoring immune Ala-Glu-Asn-OH function in thymectomized mice. Thymosin Alpha 1 has been shown to have a pleiotropic mechanism of action and a ects multiple immune cell subsets PROTOCOL that are involved in immune suppression. Studies have demonstrated improvements in immune CONTENT & POTENCY system cell subsets and the potential of TA1 for the 3000 mcg/mL subcutaneous injection INJECTION: treatment of a range of diseases. Thus, Thymosin provided in a 5 mL vial. Alpha 1, due to the immune stimulating e ects exhibited by TA1, may have utility for the treatment SUGGESTED DOSAGE INJECTION: Inject 0.15 mL subcutaneously daily of age or disease related immune suppression.

King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 CLINICAL Treatment. Vitam Horm. 2016; 102:151-78. doi: 10.1016/bs.vh. RESEARCH April 3, 2016. Epub May 24, 2016. Thymosin A1 (TA1), a thymosin-related 28-mer synthetic amino-terminal acetylated peptide, has gained increasing interest in recent years, due to its pleiotropy. The peptide has been used worldwide as an adjuvant or immunotherapeutic agent to treat disparate human diseases, including viral infections, immunodefi ciencies, and malignancies. The peptide can enhance T cell, dendritic cell (DC), and antibody responses, modulate cytokine and chemokine production, and block steroid-induced apoptosis of thymocytes. Its central role in modulating DC function and activating multiple signaling pathways that contribute to di erent functions may o er a plausible explanation for its pleiotropic action. Additionally, the ability of TA1 to activate the indoleamine 2,3-dioxygenase enzyme—which confers immune tolerance during transplantation and restrains the vicious circle of chronic infl ammation—has been a turning point, suggesting a potential, specifi c function in immunity. Accordingly, TA1 has recently been shown to promote immune reconstitution and improve survival of recipients of HLA-matched sibling T cell–depleted stem cell transplants in a phase I/II clinical trial. Thus, TA1 continues to live up to its promises.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 21 22 THYMOSIN BETA-4 THYMOSIN BETA-4 IMMUNE ENHANCER DESCRIPTION Thymosin is a hormone secreted from the thymus. Its 212 350 56 78 MOLECULAR FORMULA C H N O S primary function is to stimulate the production of T cells, MOLECULAR WEIGHT 4963.506 g/mol which are an important part of the immune system. Thymosin also assists in the SEQUENCE Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys- development of B cells to plasma cells to produce antibodies. The predominant form of Thymosin, Thymosin Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro- Beta 4, is a member of a highly conserved family of actin Leu-Pro-Ser-Lys-Glu-Thy-IleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser monomer-sequestering proteins. In addition to its role as amajor actin-sequestering molecule, Thymosin Beta 4 plays a role in tissue repair. Tß4 has been found to play an important role in protection, regeneration and remodeling PROTOCOL of injured or damaged tissues. The gene for Tß4 has also CONTENT & POTENCY been found to be one of the ﬁ rst to be upregulated after INJECTABLE: 3000mcg/ml subcutaneous injuries. Thymosin Beta 4 is currently being trialed as a injection provided in a 5ml vial. potential therapy for HIV, AIDS, and Inﬂ uenza. Thymosin Beta 4 is most often prescribed for acute injury, surgical SUGGESTED DOSAGE repair and for senior athletes. It has most recently been INJECTABLE: Inject 0.25ml subcutaneously shown to help regrow hair in addition to PRP. daily for 20 days.

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, CLINICAL Hadley ME. Source: College of Medicine, Pharmacology RESEARCH Department, University of Arizona, Tucson, USA.

Abstract: A cDNA clone encoding human thymosin-beta 4 was isolated from a cDNA library prepared from peripheral blood leukocytes of a patient with acute lymphocytic leukemia. This clone contained the entire coding sequence of 43 amino acid residues of thymosin-beta 4 and had an initiation codon and two termination codons. The amino acid and nucleotide sequences in the coding region were well conserved between rat and human. Nine of 132 nucleotides were di erent in the coding sequences (93% homology), but the deduced amino acid sequences were identical. No signal peptide was found in the deduced protein sequence. Human thymosin-beta 4 mRNA, approximately 830 nucleotides in length, was about 30 nucleotides larger than rat thymosin-beta 4 mRNA. Expression of the human thymosin-beta 4 gene in various primary myeloid and lymphoid malignant cells and in a few human hemopoietic cell lines was studied. Northern blot analyses of di erent neoplastic B lymphocytes revealed that steady state levels of thymosin-beta 4 mRNA varid as a function of di erentiation stage. Thymosin-beta 4 mRNA levels were decreased in myeloma cells as are class II human leukocyte antigen, Fc receptor, and complement receptor, suggesting a relationship between thymosin-beta 4 and the immune response. Thymosin-beta 4 mRNA was more highly expressed in mature granulocytes than in immature blastic cells. Treatment of THP-1 cells, a human monocytic cell line, with recombinant human interferon-lambda reduced the levels of thymosin-beta 4 mRNA. Its level decreased after di erentiation of THP-1 cells into Ia+ macrophages, but increased after di erentiation of HL-60 cells into Ia- macrophages. The pattern of thymosin-beta 4 gene expression suggests that it may play a fundamentalrole in the host defense mechanism.

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

800-622-4510 [email protected] wellsrx.com 23

PT-141NASAL SPRAY

WHAT IS PT-141? BENEFITS

PT-141 was developed from the peptide Patient beneﬁ ts include: Melanotan 2, which is a synthetically produced • Improves female sexual arousal disorder variant of a peptide hormone endogenously synthesized in the body that stimulates • Improves sexual disfunction in men melanogenesis that is known as alpha- (such as erectile dysfunction or impotence) Melanocyte stimulating hormone. PT-141 has been shown in studies to provide libido- enhancing e ects by activating the melanocortin receptors MC1R and MC4R, without tanning the SIDE EFFECTS skin. Side e ects for males and females may PT-141 is an FDA approved therapy for the include: treatment of female hypoactive sexual desire disorder. Studies have shown that PT-141 does • Nausea • Flushing • Headache not act on the vascular system and exhibits a clinically signiﬁ cant increase in sexual desire.

TYPICAL PRESCRIBING PROTOCOL:

MALE & FEMALE: • Male or Female patients may begin with intranasal administration of 2mg (1 spray in each nostril) 30 minutes prior to sexual activity.

• The dose may be titrated up to 4mg (2 sprays in each nostril) as tolerated or desired.

800-622-4510 [email protected] wellsrx.com

“The claims and statements have been evaluated as well as accepted by the FDA.”

REFERENCE: SHADIACK, AM, ET AL. “MELANOCORTINS IN THE TREATMENT OF MALE AND FEMALE SEXUAL DYSFUNCTION.” CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007) 7: 1137. HTTP://WWW.EUREKASELECT.COM/78412/ARTICLE

Women may face a variety of challenges when it comes to sexual wellness ranging from poor lubrication and low libido to vaginal tissue health issues or painful intercourse. These issues can stand in the way of an active, healthy sex life. Through Wells Pharmacy Sexual Wellness Program, you can support your female patients in overcoming these obstacles with a variety of preparations to address their needs. “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

ADDRESSING SEXUAL WELLNESS NEEDS

Program kits contain complementary medications made with prescription grade ingredients and do not contain controlled substances. No hormones are added since many women are Kits are available in 90-day supplies and to receiving hormone treatment already. the extend permitted • A gel of sildenafi l/arginine, with or without menthol, may be benefi cial when applied 15-30 pursuant to a valid minutes before sexual activity to support improved libido. The body converts L-arginine into prescription. nitric oxide. Increased nitric oxide causes blood vessels to open wider for improved blood fl ow. Ordering can be • A rapid dissolve tablet of oxytocin can serve as a mood booster or enhancer as well. done through your • A gel containing Vitamin E, DHEA and Hyaluronic Acid serves as a natural lubricant to ease Sales Representative potential discomfort during sexual activity and may enhance sex drive, and promote collagen formation.

ADDRESSING SEXUAL WELLNESS NEEDS Issues such as low libido or painful intercourse no longer have to stand in the way of women having an active and enjoyable sex life. Wells Pharmacy Network’s Sexual Wellness Program enables you to prescribe the formulations women need for improved sexual health and activity.

For questions about the Wells Sexual Wellness Program contact your Sales Representative.

800-622-4510 [email protected] wellsrx.com

* THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL. ONLY YOUR PHYSICIAN CAN DETERMINE WHETHER A PARTICULAR FORMULATION IS RIGHT FOR YOU. 25 SEXUAL WELLNESS PROGRAM FOR MEN PHYSICIAN INFORMATION

Erectile dysfunction and low sex drive or libido are issues that many men face when it comes to their sexual health. These problems can not only be frustrating, but put a strain on relationships. With Wells Pharmacy Sexual Wellness Program, you can provide patients with a variety of preparations to increase sexual enhancement, reduce erectile dysfunction, and improve sex drive. Oral medications are recommended ﬁ rst, and if these do not produce desired results, there are injectable medications available as well.

ENHANCING SEXUAL WELLNESS To address erectile dysfunction and sexual enhancement, program kits o er several options:

• Rapid dissolve tablets that combine oxytocin with tadalafi l can be taken daily to help maintain muscle response and blood fl ow for more satisfying erections in those with erectile dysfunction. It is also used and helps with males that have BPH. • An injectable trimix (papaverine/phentolamine/alprostadil) may be tested fi rst in the o ce to fi nd the appropriate dosage and provide injection training. Injections twice a week can help to activate muscle response and blood fl ow. • Arginine and Citrulline capsules may help boost Nitric Oxide and promote blood fl ood within the body. • Rapid dissolve tablets of oxytocin alone can be prescribed as a sexual enhancer to support more satisfactory sexual wellness.

PROMOTING SEXUAL WELLNESS IN MEN With the right combination of medications, men can enjoy an active sex life at virtually any age. Wells Pharmacy Network’s Sexual Wellness Program enables you to prescribe the medications men need for improved sexual health and activity with options for reﬁ ll every 90 days, or as necessary and to the extent permitted pursuant to a valid prescription. For questions about the Wells Sexual Wellness Program contact your Sales Representative.

For questions about the Wells Sexual Wellness Program contact your Sales Representative.

800-622-4510 [email protected] wellsrx.com

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

* THE INFORMATION PROVIDED HERE IS FOR REFERENCE ONLY AND IS NOT TO BE RELIED UPON AS MAKING ANY REPRESENTATION AS TO THE EFFICACY OF ANY PARTICULAR FORMULATIONS. THE SAMPLE FORMULATIONS DESCRIBED HERE IN RESULT FROM PRESCRIPTIONS PREVIOUSLY ORDERED BY PROFESSIONALS LICENSED TO WRITE PRESCRIPTIONS IN THEIR RESPECTIVE DISCIPLINE. NOTHING HERE IS INTENDED TO REPLACE OR INFLUENCE THE INDEPENDENT JUDMENT OF ANY LICENSED PROFESSIONAL. ONLY YOUR PHYSICIAN CAN DETERMINE WHETHER A PARTICULAR FORMULATION IS RIGHT FOR YOU. 25 Optimize Your Immune System by Wells Pharmacy Network

There has never been a better time to optimize your immune system. With that in mind, the pharmacists of Wells Pharmacy Network are launching Quad Immune. As the name suggest, Quad Immune consists of four products carefully selected by pharmacist from Wells’ formulary for their clinically demonstrated e ects on the immune system. Quad Immune’s combination of synergistic products allows for your immune system to function at its optimal state aiding in ﬁ ghting and resisting the underlying cause of infections.

This package includes: • One sterile vial of Thymosin A1 at 3000 mcg/mL provided in a 5 mL vial for subcutaneous injection • 30 mL vial of B-Complex containing B2, B3, B6, B12 as Cyanocobalamin, (2 mg / 20 mg / 2mg / 300 mcg) and Vitamin C (20 mg) / mL • Zinc 30 mg (as Zinc Picolinate) 30 capsules • Vitamin D3 2000 iu (as Cholecalciferol), 30 capsules

B+C Vitamin B Complex + Vitamin C TA1 THYMOSIN A1 VITAMIN C HAS BEEN SHOWN TO: STUDIES HAVE SHOWN THAT THYMOSIN A1: • Beneﬁ t the “cytokine storm” response • Regulates immune system response • A ect the development and maturation of T-lymphocytes • Modulates anti-viral cytokine production Including NK (natural Killer) cells involved in the immune response to viral agents • Promotes T-cell maturation and di erentiation • Reduces oxidatives stress • Upregulates MHC Class 1 expression • Inhibits systemic inﬂ ammation • Inhibits viral replication B-COMPLEX HAS BEEN SHOWN TO: • Aid the body’s ability to prevent infections • Promotes cellular health and growth of red blood cells • Be a key component in the development and maintenance of a healthy immune system

Z ZINC D Vitamin D ZINC HAS BEEN SHOWN TO: • Support the proliferation of immune cells • Decrease the incidence and duration of infections VITAMIN D REPORTED CLINICAL EFFECTS: • Reduce inﬂ ammation • Demonstrated reduction in viral replication rates • Reduce in total mortality of elderly subjects by 27% • Decrease in inﬂ ammatory response • Reduction in illness severity

QUAD IMMUNE 800-622-4510 [email protected] wellsrx.com by Wells Pharmacy Network 2020 PRODUCT CATALOG WELLS PHARMACY NETWORK

800-622-4510 [email protected] wellsrx.com